Literature DB >> 19620880

Effect of hydrogen sulfide in a porcine model of myocardial ischemia-reperfusion: comparison of different administration regimens and characterization of the cellular mechanisms of protection.

Robert M Osipov1, Michael P Robich, Jun Feng, Yuhong Liu, Richard T Clements, Hilary P Glazer, Neel R Sodha, Csaba Szabo, Cesario Bianchi, Frank W Sellke.   

Abstract

OBJECTIVE: We investigate the impact of different regimens of parenteral hydrogen sulfide (H2S) administration on myocardium during ischemia-reperfusion (IR) and the molecular pathways involved in its cytoprotective effects.
METHODS: Eighteen male Yorkshire pigs underwent 60 minutes of mid-left anterior descending coronary artery occlusion followed by 120 minutes of reperfusion. Pigs received either placebo (control, n = 6) or H2S as a bolus (bolus group, n = 6, 0.2 mg/kg over 10 seconds at the start of reperfusion) or as an infusion (infusion group, n = 6, 2 mg.kg.h initiated at the onset of ischemia and continued into the reperfusion period). Myocardial function was monitored throughout the experiment. The area at risk and myocardial necrosis was determined by Monastral blue/triphenyl tetrazolium chloride staining. Apoptosis and the expression pattern of various intracellular effector pathways were investigated in the ischemic territory. Coronary microvascular reactivity to endothelium-dependent and endothelium-independent factors was measured.
RESULTS: H2S infusion but not bolus administration markedly reduce myocardial infarct size (P < 0.05) and improve regional left ventricular function, as well as endothelium-dependent and endothelium-independent microvascular reactivity (P < 0.05). The expression of B-cell lymphoma 2 (P = 0.059), heat shock protein 27 and alphaB-crystallin (P < 0.05) were lower in H2S-treated groups. Infusion of H2S caused higher expression of phospho-glycogen synthase kinase-3 beta isoform(P < 0.05) and lower expression of mammalian target of rapamycin and apoptosis-inducing factor (P < 0.05). Bolus of H2S caused higher expression of phospho-p44/42 MAPK extracellular signal-regulated kinase and lower expression of Beclin-1 (P < 0.05). The expression of caspase 3 and cleaved caspase 3 were lower (P < 0.05), whereas the expression of phospho-Bad(Ser136) was higher in the bolus group versus control and infusion groups (P < 0.05). The terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cell count was lower in both H2S-treated groups compared with the control (P < 0.05).
CONCLUSIONS: This study demonstrates that infusion of H2S is superior to a bolus alone in reducing myocardial necrosis after IR injury, even though some markers of apoptosis and autophagy were affected in both H2S-treated groups. Thus, the current results indicate that infusion of H2S throughout IR may offer better myocardial protection from IR injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620880     DOI: 10.1097/FJC.0b013e3181b2b72b

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  40 in total

Review 1.  Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part II. Pathophysiological and therapeutic aspects.

Authors:  Katalin Módis; Eelke M Bos; Enrico Calzia; Harry van Goor; Ciro Coletta; Andreas Papapetropoulos; Mark R Hellmich; Peter Radermacher; Frédéric Bouillaud; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

2.  Cardioprotection by H2S engages a cGMP-dependent protein kinase G/phospholamban pathway.

Authors:  Sofia-Iris Bibli; Ioanna Andreadou; Athanasia Chatzianastasiou; Christos Tzimas; Despina Sanoudou; Evangelia Kranias; Peter Brouckaert; Ciro Coletta; Csaba Szabo; Dimitrios Th Kremastinos; Efstathios K Iliodromitis; Andreas Papapetropoulos
Journal:  Cardiovasc Res       Date:  2015-04-13       Impact factor: 10.787

3.  Cardioprotective effects of hydrogen sulfide.

Authors:  Gábor Szabó; Gábor Veres; Tamás Radovits; Domokos Gero; Katalin Módis; Christiane Miesel-Gröschel; Ferenc Horkay; Matthias Karck; Csaba Szabó
Journal:  Nitric Oxide       Date:  2010-11-19       Impact factor: 4.427

Review 4.  H2S during circulatory shock: some unresolved questions.

Authors:  Oscar McCook; Peter Radermacher; Chiara Volani; Pierre Asfar; Anita Ignatius; Julia Kemmler; Peter Möller; Csaba Szabó; Matthew Whiteman; Mark E Wood; Rui Wang; Michael Georgieff; Ulrich Wachter
Journal:  Nitric Oxide       Date:  2014-03-18       Impact factor: 4.427

5.  Characterization of zofenoprilat as an inducer of functional angiogenesis through increased H2 S availability.

Authors:  E Terzuoli; M Monti; V Vellecco; M Bucci; G Cirino; M Ziche; L Morbidelli
Journal:  Br J Pharmacol       Date:  2015-03-27       Impact factor: 8.739

6.  Development of hydrogen sulfide-based therapeutics for cardiovascular disease.

Authors:  Benjamin L Predmore; David J Lefer
Journal:  J Cardiovasc Transl Res       Date:  2010-07-14       Impact factor: 4.132

Review 7.  The potentials of distinct functions of autophagy to be targeted for attenuation of myocardial ischemia/reperfusion injury in preclinical studies: an up-to-date review.

Authors:  Behnaz Mokhtari; Reza Badalzadeh
Journal:  J Physiol Biochem       Date:  2021-06-26       Impact factor: 4.158

8.  Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on myocardial function and perfusion.

Authors:  Michael P Robich; Louis M Chu; Thomas A Burgess; Jun Feng; Cesario Bianchi; Frank W Sellke
Journal:  J Cardiovasc Pharmacol       Date:  2011-01       Impact factor: 3.105

Review 9.  Hydrogen sulfide and ischemia-reperfusion injury.

Authors:  Chad K Nicholson; John W Calvert
Journal:  Pharmacol Res       Date:  2010-06-11       Impact factor: 7.658

10.  Dynamic change of hydrogen sulfide after traumatic brain injury and its effect in mice.

Authors:  Mingyang Zhang; Haiyan Shan; Tao Wang; Weili Liu; Yaoqi Wang; Long Wang; Lu Zhang; Pan Chang; Wenwen Dong; Xiping Chen; Luyang Tao
Journal:  Neurochem Res       Date:  2013-01-17       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.